Draft:CT-996

Submission declined on 22 September 2024 by Bhairava7 (talk).

Creator not improved this draft per suggested by the other Afc reviewers, I've thought if the Template:Drugbox is added in the draft then it should be acceptable.

If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Declined by Bhairava7 59 days ago. Last edited by Bhairava7 59 days ago. Reviewer: Inform author.

Resubmit

Please note that if the issues are not fixed, the draft will be declined again.

Comment: You may improve this by adding a Template:Drugbox Pygos (talk) 04:52, 2 September 2024 (UTC)

CT-996 is an once daily oral small molecule GLP-1 agonist developed to treat obesity and type 2 diabetes.^[1] It is designed with minimal-to-no beta-arrestin recruitment.^[2] In a double-blind, randomized, placebo-controlled Phase I clinical trial participants averaged 6.1 percent placebo adjusted weight loss within four weeks.^[3]^[4]^[5]^[6] The drug is being developed by Roche/Genentech after Roche's takeover of Carmot Therapeutics in January 2024.^[7]^[8]

References

^ owenhaskins (2023-10-12). "Carmot's CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes". Bariatric News. Retrieved 2024-07-28.
^ "Clinical Trials | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
^ "Roche - Press release, July 17, 2024". www.roche.com. Retrieved 2024-07-26.
^ "CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes". PharmExec. 2024-07-18. Retrieved 2024-07-26.
^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-28.
^ "Handelsblatt". www.handelsblatt.com (in German). Retrieved 2024-07-28.
^ Brody, Micaela (2024-01-29). "Carmot Therapeutics Announces Completion of Acquisition by Roche | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
^ Burger, Ludwig (December 4, 2023). "Roche joins race for obesity drugs with $2.7 billion Carmot deal". Reuters. Retrieved July 28, 2024.

[1] wenhaskins (2023-10-12). "Carmot's CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes". Bariatric News. Retrieved 2024-07-28.

[2] "Clinical Trials | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.

[3] "Roche - Press release, July 17, 2024". www.roche.com. Retrieved 2024-07-26.

[4] "CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes". PharmExec. 2024-07-18. Retrieved 2024-07-26.

[5] "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-28.

[6] "Handelsblatt". www.handelsblatt.com (in German). Retrieved 2024-07-28.

[7] Brody, Micaela (2024-01-29). "Carmot Therapeutics Announces Completion of Acquisition by Roche | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.

[8] Burger, Ludwig (December 4, 2023). "Roche joins race for obesity drugs with $2.7 billion Carmot deal". Reuters. Retrieved July 28, 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]